A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, Phase 2 trial. Lancet Oncol. 2016;17(9):1317–1324. doi:10.1016/S1470-2045(16)30196-6
   PubMed Web of Science ®Google Scholar
• Marchioni M, Bandini M, Pompe RS, et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Int Urol Nephrol. 2017;49(12):2143–2149. doi:10.1007/s11255-017-1703-y
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731. doi:10.1056/NEJMoa1303989
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590. doi:10.1200/JCO.2008.20.1293
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;2018:14.
   Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi:10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi:10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi:10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:2801–2811. doi:10.2147/DDDT.S109640
   PubMed Web of Science ®Google Scholar
• Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs RD. 2011;11(2):113–126. doi:10.2165/11591240-000000000-00000
   PubMedGoogle Scholar
• Pithavala YK, Chen Y, Toh M, et al. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemother Pharmacol. 2012;70(1):103–112. doi:10.1007/s00280-012-1888-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Inlyta (Axitinib): EU EPAR public assessment report; 2012.
   Google Scholar
• Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK. Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013;52(9):713–725. doi:10.1007/s40262-013-0068-3
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol off J Am Soc Clin Oncol. 2005;23(24):5474–5483. doi:10.1200/JCO.2005.04.192
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res off J Am Assoc Cancer Res. 2011;17(11):3841–3849. doi:10.1158/1078-0432.CCR-10-2806
   PubMed Web of Science ®Google Scholar
• Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma. Clin Pharmacokinet. 2015;54(4):397–407. doi:10.1007/s40262-014-0207-5
   PubMed Web of Science ®Google Scholar
• Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53(5):491–504. doi:10.1002/jcph.73
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233–1242. doi:10.1016/S1470-2045(13)70464-9
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Fishman MN, et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol off J Eur Soc Med Oncol. 2015;26(7):1372–1377. doi:10.1093/annonc/mdv103
   PubMed Web of Science ®Google Scholar
• Chen Y, Suzuki A, Tortorici MA, et al. Axitinib plasma pharmacokinetics and ethnic differences. Invest New Drugs. 2015;33(2):521–532. doi:10.1007/s10637-015-0214-x
   PubMed Web of Science ®Google Scholar
• Chen Y, Rini BI, Motzer RJ, et al. Effect of renal impairment on the pharmacokinetics and safety of axitinib. Target Oncol. 2016;11(2):229–234. doi:10.1007/s11523-015-0389-2
   PubMed Web of Science ®Google Scholar
• Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012;68(5):645–655. doi:10.1007/s00228-011-1171-8
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108:1034–1041. doi:10.1038/bjc.2013.58.bjc201358
   PubMed Web of Science ®Google Scholar
• Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol off J Eur Soc Med Oncol ESMO. 2010;21(8):1594–1598. doi:10.1093/annonc/mdp605
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Toh M, Rahavendran SV, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs. 2011;29(6):1370–1380. doi:10.1007/s10637-010-9477-4
   PubMed Web of Science ®Google Scholar
• Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014;89:179–196. doi:10.1016/j.critrevonc.2013.08.007S1040-8428(13)00184-4[pii]
   PubMed Web of Science ®Google Scholar
• Pithavala YK, Tong W, Mount J, et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs. 2012;30(1):273–281. doi:10.1007/s10637-010-9511-6
   PubMed Web of Science ®Google Scholar
• Gomo C, Coriat R, Faivre L, et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011;29(6):1511–1514. doi:10.1007/s10637-010-9514-3
   PubMed Web of Science ®Google Scholar
• Da Silva F, Thomas-Schoemann A, Huillard O, Goldwasser F, Blanchet B. Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker. Ann Oncol off J Eur Soc Med Oncol. 2016;27(8):1651–1652. doi:10.1093/annonc/mdw182
   PubMed Web of Science ®Google Scholar
• Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol. 2010;65(3):563–570. doi:10.1007/s00280-009-1065-y
   PubMed Web of Science ®Google Scholar
• Tzogani K, Skibeli V, Westgaard I, et al. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2015;20(2):196–201. doi:10.1634/theoncologist.2014-0177
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–562. doi:10.1016/S1470-2045(13)70093-7
   PubMed Web of Science ®Google Scholar
• Huillard O, Boissier E, Blanchet B, et al. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opin Drug Saf. 2014;13(5):663–673. doi:10.1517/14740338.2014.907270
   PubMed Web of Science ®Google Scholar
• Arrondeau J, Mir O, Boudou-Rouquette P, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30(5):2046–2049. doi:10.1007/s10637-011-9764-8
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist. 2012;17(9):1204–1212. doi:10.1634/theoncologist.2011-0439
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Carton E, Mir O, et al. Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. Invest New Drugs. 2014;32(3):569–572. doi:10.1007/s10637-013-0052-7
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Thomas-Schoemann A, Bellesoeur A, Goldwasser F. Sorafenib for patients with differentiated thyroid cancer. Lancet. 2015;385(9964):227–228. doi:10.1016/S0140-6736(15)60054-X
   PubMed Web of Science ®Google Scholar
• Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49:1109–1114. doi:10.1016/j.jpba.2009.02.008.S0731-7085(09)00112-5
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Bavencio (Avelumab): EU EPAR public assessment report; 2022.
   Google Scholar
• Heery CR, O’Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598. doi:10.1016/S1470-2045(17)30239-5
   PubMed Web of Science ®Google Scholar
• Sheng J, Srivastava S, Sanghavi K, et al. Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol. 2017;57(Suppl 10):S26–S42. doi:10.1002/jcph.990
   PubMed Web of Science ®Google Scholar
• Novakovic AM, Wilkins JJ, Dai H, et al. Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma. Clin Pharmacol Ther. 2020;107(3):588–596. doi:10.1002/cpt.1645
   PubMed Web of Science ®Google Scholar
• Wilkins JJ, Brockhaus B, Dai H, et al. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma. CPT Pharmacomet Syst Pharmacol. 2019;8(6):415–427. doi:10.1002/psp4.12406
   PubMedGoogle Scholar
• Powles T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511–1519. doi:10.1016/j.annonc.2021.09.014
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–1157. doi:10.1158/2326-6066.CIR-15-0059
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014;32(15_suppl):5010. doi:10.1200/jco.2014.32.15_suppl.5010
   Web of Science ®Google Scholar
• Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol Baltim Md. 2005;174(1):215–222. doi:10.4049/jimmunol.174.1.215
   PubMed Web of Science ®Google Scholar
• Sidibe A, Ropraz P, Jemelin S, et al. Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours. Nat Commun. 2018;9(1):355. doi:10.1038/s41467-017-02610-0
   PubMed Web of Science ®Google Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101(12):4878–4886. doi:10.1182/blood-2002-07-1956
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148. doi:10.1084/jem.20140559
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539–549. doi:10.1158/0008-5472.CAN-12-2325
   PubMed Web of Science ®Google Scholar
• Hirsch L, Flippot R, Escudier B, Albiges L. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. 2020;80(12):1169–1181. doi:10.1007/s40265-020-01327-7
   PubMed Web of Science ®Google Scholar
• Yuan H, Cai P, Li Q, et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed Pharmacother. 2014;68(6):751–756. doi:10.1016/j.biopha.2014.07.002
   PubMed Web of Science ®Google Scholar
• Morelli MB, Amantini C, Santoni M, et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget. 2015;6(34):36245–36259. doi:10.18632/oncotarget.5768
   PubMedGoogle Scholar
• Läubli H, Müller P, D’Amico L, Buchi M, Kashyap AS, Zippelius A. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunol Immunother CII. 2018;67(5):815–824. doi:10.1007/s00262-018-2136-x
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171–6180. doi:10.1158/0008-5472.CAN-10-0153
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–615. doi:10.1038/nm.3541
   PubMed Web of Science ®Google Scholar
• Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res. 2010;70(14):5728–5739. doi:10.1158/0008-5472.CAN-09-4672
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 2011;475(7355):226–230. doi:10.1038/nature10169
   PubMed Web of Science ®Google Scholar
• Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943–2948. doi:10.1158/0008-5472.CAN-12-4354
   PubMed Web of Science ®Google Scholar
• Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561–17566. doi:10.1073/pnas.1215397109
   PubMed Web of Science ®Google Scholar
• Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003;33(11):3117–3126. doi:10.1002/eji.200324270
   PubMed Web of Science ®Google Scholar
• Lu Y, Yang W, Qin C, et al. Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol Baltim Md. 2009;183(10):6413–6421. doi:10.4049/jimmunol.0901073
   PubMed Web of Science ®Google Scholar
• Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–324. doi:10.1038/nrclinonc.2018.9
   PubMed Web of Science ®Google Scholar
• Tian L, Goldstein A, Wang H, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250–254. doi:10.1038/nature21724
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2021;31:1030–1039. doi:10.1016/j.annonc.2020.04.010
   Web of Science ®Google Scholar
• Masters JC, Khandelwal A, Di Pietro A, Dai H, Brar S. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma (aRCC). CPT Pharmacomet Syst Pharmacol. 2022;11(4):458–468. doi:10.1002/psp4.12771
   PubMedGoogle Scholar
• Bosma NA, Warkentin MT, Gan CL, et al. Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci. 2022;37:14–26. doi:10.1016/j.euros.2021.12.007
   PubMedGoogle Scholar
• Quhal F, Mori K, Bruchbacher A, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4(5):755–765. doi:10.1016/j.euo.2021.03.001
   PubMed Web of Science ®Google Scholar
• Riaz IB, He H, Ryu AJ, et al. A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. Eur Urol. 2021;80(6):712–723. doi:10.1016/j.eururo.2021.03.016
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Schöffski P, Ravaud A, et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):275. doi:10.1186/s40425-019-0746-2
   PubMed Web of Science ®Google Scholar
• Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010–2017. doi:10.1002/cncr.31293
   PubMed Web of Science ®Google Scholar
• Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E. Network meta-analysis comparing efficacy, safety and tolerability of anti-PD-1/PD-L1 antibodies in solid cancers. J Cancer. 2021;12(14):4372–4378. doi:10.7150/jca.57413
   PubMed Web of Science ®Google Scholar
• Sonpavde GP, Grivas P, Lin Y, Hennessy D, Hunt JD. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol Lond Engl. 2021;17(19):2545–2558. doi:10.2217/fon-2020-1222
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. doi:10.1016/j.ctrv.2016.02.001
   PubMed Web of Science ®Google Scholar
• de Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312–318. doi:10.1158/2326-6066.CIR-16-0237
   PubMed Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14(13):1287–1294. doi:10.1016/S1470-2045(13)70465-0
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet Lond Engl. 2011;378(9807):1931–1939. doi:10.1016/S0140-6736(11)61613-9
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19(4):451–460. doi:10.1016/S1470-2045(18)30107-4
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6(1):109. doi:10.1186/s40425-018-0420-0
   PubMed Web of Science ®Google Scholar
• Rini BI, Battle D, Figlin RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7(1):354. doi:10.1186/s40425-019-0813-8
   PubMed Web of Science ®Google Scholar
• Haanen JB, Carbonnel G, Robert C F, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2017;28(suppl_4):iv119–iv142. doi:10.1093/annonc/mdx225
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z
   PubMed Web of Science ®Google Scholar
• Grünwald V, Voss MH, Rini BI, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. Br J Cancer. 2020;123(6):898–904. doi:10.1038/s41416-020-0949-9
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB, Choueiri TK, et al. Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2021;19(5):e306–e312. doi:10.1016/j.clgc.2021.03.019
   PubMed Web of Science ®Google Scholar
• Allison J, Charnley N, Stevenson R, Waddell T, Pillai MR. Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): a real-world outcome review in the Northwest of England, United Kingdom. J Clin Oncol. 2021;39(6_suppl):294. doi:10.1200/JCO.2021.39.6_suppl.294
   Web of Science ®Google Scholar
• Flippot R, Dalban C, Laguerre B, et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol off J Am Soc Clin Oncol. 2019;37(23):2008–2016. doi:10.1200/JCO.18.02218
   PubMed Web of Science ®Google Scholar
• Emamekhoo H, Olsen MR, Carthon BC, et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: checkMate 920. Cancer. 2022;128(5):966–974. doi:10.1002/cncr.34016
   PubMed Web of Science ®Google Scholar
• Brown LC, Desai K, Wei W, et al. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. J Immunother Cancer. 2021;9(9):e003281. doi:10.1136/jitc-2021-003281
   PubMed Web of Science ®Google Scholar
• Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(8):765–772. doi:10.1200/JCO.2017.74.7352
   PubMed Web of Science ®Google Scholar
• Blum KA, Gupta S, Tickoo SK, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17(12):659–678. doi:10.1038/s41585-020-00382-9
   PubMed Web of Science ®Google Scholar
• Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol off J Am Soc Clin Oncol. 2009;27(2):235–241. doi:10.1200/JCO.2008.18.0000
   PubMed Web of Science ®Google Scholar
• Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2021;27(1):78–86. doi:10.1158/1078-0432.CCR-20-2063
   PubMed Web of Science ®Google Scholar
• Choueiri TK. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open. 2021;6(3):12.
   Web of Science ®Google Scholar
• Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142. doi:10.1371/journal.pone.0130142
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. a systematic review and meta-analysis. Target Oncol. 2016;11(2):143–148. doi:10.1007/s11523-015-0392-7
   PubMed Web of Science ®Google Scholar
• Mori K, Abufaraj M, Mostafaei H, et al. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2020. doi:10.1016/j.eururo.2020.10.006
   Web of Science ®Google Scholar
• Noel J, Huillard O, Goldwasser F, et al. The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis Eur Urol. 2021;79(4):e112. doi:10.1016/j.eururo.2021.01.013
   PubMed Web of Science ®Google Scholar
• Damotte D, Warren S, Arrondeau J, et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J Transl Med. 2019;17(1):357. doi:10.1186/s12967-019-2100-3
   PubMed Web of Science ®Google Scholar
• Zhu J, Armstrong AJ, Friedlander TW, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6(1):4. doi:10.1186/s40425-018-0314-1
   PubMed Web of Science ®Google Scholar
• Larrinaga G, Solano-Iturri JD, Errarte P, et al. Soluble PD-L1 is an independent prognostic factor in clear cell renal cell carcinoma. Cancers. 2021;13(4):667. doi:10.3390/cancers13040667
   PubMed Web of Science ®Google Scholar
• Zizzari IG, Napoletano C, Di Filippo A, et al. Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma. Cancers. 2020;12(9):E2620. doi:10.3390/cancers12092620
   PubMed Web of Science ®Google Scholar
• Tiako Meyo M, Jouinot A, Fabre E, et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12(2):473. doi:10.3390/cancers12020473
   PubMed Web of Science ®Google Scholar
• Epaillard N, Simonaggio A, Elaidi R, et al. BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bull Cancer. 2020;107(5S):eS22–eS27. doi:10.1016/S0007-4551(20)30283-6
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020;26(11):1733–1741. doi:10.1038/s41591-020-1044-8
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Arrondeau J, Gervais C, et al. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: the ELY study. EBioMedicine. 2021;73:103630. doi:10.1016/j.ebiom.2021.103630
   PubMed Web of Science ®Google Scholar
• Vazeille C, Jouinot A, Durand JP, et al. Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. Am J Clin Nutr. 2017;105(5):1139–1147. doi:10.3945/ajcn.116.140434
   PubMed Web of Science ®Google Scholar
• Hirsch L, Bellesoeur A, Boudou-Rouquette P, et al. The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer Oxf Engl. 2020;124:170–177. doi:10.1016/j.ejca.2019.11.003
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–1444. doi:10.1093/annonc/mdy103
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5(12):1774. doi:10.1001/jamaoncol.2019.2785
   PubMed Web of Science ®Google Scholar
• Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10(3):424–428. doi:10.1080/19490976.2018.1527167
   PubMed Web of Science ®Google Scholar
• Matson V, Chervin CS, Gajewski TF. Cancer and the microbiome—influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology. 2021;160(2):600–613. doi:10.1053/j.gastro.2020.11.041
   PubMed Web of Science ®Google Scholar
• Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science. 2021;371(6529):595–602. doi:10.1126/science.abf3363
   PubMed Web of Science ®Google Scholar
• Dizman N, Meza L, Bergerot P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704–712. doi:10.1038/s41591-022-01694-6
   PubMed Web of Science ®Google Scholar
• Pal SK, Li SM, Wu X, et al. Stool bacteriomic profiling in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitors. Clin Cancer Res off J Am Assoc Cancer Res. 2015;21(23):5286–5293. doi:10.1158/1078-0432.CCR-15-0724
   PubMed Web of Science ®Google Scholar
• Ianiro G, Rossi E, Thomas AM, et al. Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nat Commun. 2020;11(1):4333. doi:10.1038/s41467-020-18127-y
   PubMed Web of Science ®Google Scholar
• Dizman N, Hsu J, Bergerot PG, et al. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Med. 2021;10(1):79–86. doi:10.1002/cam4.3569
   PubMed Web of Science ®Google Scholar
• Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441–464. doi:10.1007/s00228-020-03014-8
   PubMed Web of Science ®Google Scholar
• Bardin C, Veal G, Paci A, et al. Therapeutic drug monitoring in cancer–are we missing a trick? Eur J Cancer Oxf Engl. 2014;50(12):2005–2009. doi:10.1016/j.ejca.2014.04.013
   PubMed Web of Science ®Google Scholar
• Cerbone L, Combarel D, Geraud A, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6(6):100312. doi:10.1016/j.esmoop.2021.100312
   PubMed Web of Science ®Google Scholar
• Cabel L, Blanchet B, Thomas-Schoemann A, et al. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam Clin Pharmacol. 2018;32(1):98–107. doi:10.1111/fcp.12327
   PubMed Web of Science ®Google Scholar
• Beinse G, Hulin A, Rousseau B. Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma. Invest New Drugs. 2019;37(6):1289–1291. doi:10.1007/s10637-019-00743-1
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Nagai H, Matsui D. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. Cancer Chemother Pharmacol. 2021;89(1):11. doi:10.1007/s00280-021-04359-2
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Ollier E, Allard M, et al. Is there an exposure–response relationship for nivolumab in real-world NSCLC patients?. Cancers. 2019;16.
   PubMed Web of Science ®Google Scholar